Pharmaceutical care for patients with acute myocardial infarction in Hungary

Márton Argay, István Koós, István Takács, Irina Dormaeva, Andrea Meskó, R. Zelkó, Balázs Hankó

Research output: Contribution to journalArticle

Abstract

Objective: To obtain information on the main causatives of acute myocardial infarction (AMI), the background needs to be analyzed. Our aim was to identify those pharmaceutical aspects of this polymorbidity where the pharmacist can contribute. Earlier and recent European and Hungarian studies show similar results: cardiovascular (CV) death is still the leading cause of mortality. The quality of life is much lower and life expectancy is shorter in the investigated Borsod-Abaúj Zemplén county population compared to the whole of the country. After pharmaceutical care has been defined, its role should be established. Methods: A retrospective hospital-based survey was carried out. Medical records of 659 patients treated for myocardial infarction at the 1 st Department of Internal Medicine-Cardiology of Borsod-Abaúj- Zemplén County Hospital and University Hospital were analyzed. Data were obtained using the MedWorkS integrated hospital information system and were selected based on Social Security Number (TAJ) and The International Statistical Classification of Diseases and Related Health Problems (ICD). We focused on the therapy and medication of patients. Results: The obtained results are consistent with those of previous Hungarian studies (OLEF 2000) and statistical analyses. Based on the present study we suggest that pharmacists should work more closely with the medical staff. In studying the medication, we concentrated on antiplatelet therapy and studied the use of aspirin alone compared to aspirin plus clopidogrel. Of the 659 patients only 172 received aspirin as a preventive agent. We noticed that during this study only a low number of patients received ASA treatment and it could be seen in the outcome of the illness. We also found that dual antiplatelet therapy did not decrease the incidence of reinfarction in patients with AMI. Discussion: In this study the theory (guidelines, other studies) and the clinical practice of the therapy and medication of AMI were compared. ASA therapy did not produce any significant effect. Our results are similar to those studies which concluded that ASA did not decrease the risk of cardiovascular events. Conclusion: Most patients with AMI suffer from polymorbidity. Since the occurrence of underlying chronic diseases is high, not only AMI must be treated, but therapy and medication must be complex. Complex therapeutic management is the key to the success of pharmaceutical care in the community pharmacy following hospital treatment.

Original languageEnglish
Pages (from-to)91-95
Number of pages5
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Pharmaceutical Services
Hungary
Myocardial Infarction
Aspirin
Therapeutics
clopidogrel
Pharmacists
Hospital Information Systems
County Hospitals
Social Security
Pharmacies
Medical Staff
International Classification of Diseases
Internal Medicine
Life Expectancy
Cardiology
Medical Records
Chronic Disease
Quality of Life
Guidelines

Keywords

  • Acute myocardial infarction
  • Complex therapy
  • Patients Polymorbid
  • Pharmaceutical care

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmaceutical care for patients with acute myocardial infarction in Hungary. / Argay, Márton; Koós, István; Takács, István; Dormaeva, Irina; Meskó, Andrea; Zelkó, R.; Hankó, Balázs.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 51, No. 2, 02.2013, p. 91-95.

Research output: Contribution to journalArticle

Argay, Márton ; Koós, István ; Takács, István ; Dormaeva, Irina ; Meskó, Andrea ; Zelkó, R. ; Hankó, Balázs. / Pharmaceutical care for patients with acute myocardial infarction in Hungary. In: International Journal of Clinical Pharmacology and Therapeutics. 2013 ; Vol. 51, No. 2. pp. 91-95.
@article{db55621663d74c0bace2e512597ee517,
title = "Pharmaceutical care for patients with acute myocardial infarction in Hungary",
abstract = "Objective: To obtain information on the main causatives of acute myocardial infarction (AMI), the background needs to be analyzed. Our aim was to identify those pharmaceutical aspects of this polymorbidity where the pharmacist can contribute. Earlier and recent European and Hungarian studies show similar results: cardiovascular (CV) death is still the leading cause of mortality. The quality of life is much lower and life expectancy is shorter in the investigated Borsod-Aba{\'u}j Zempl{\'e}n county population compared to the whole of the country. After pharmaceutical care has been defined, its role should be established. Methods: A retrospective hospital-based survey was carried out. Medical records of 659 patients treated for myocardial infarction at the 1 st Department of Internal Medicine-Cardiology of Borsod-Aba{\'u}j- Zempl{\'e}n County Hospital and University Hospital were analyzed. Data were obtained using the MedWorkS integrated hospital information system and were selected based on Social Security Number (TAJ) and The International Statistical Classification of Diseases and Related Health Problems (ICD). We focused on the therapy and medication of patients. Results: The obtained results are consistent with those of previous Hungarian studies (OLEF 2000) and statistical analyses. Based on the present study we suggest that pharmacists should work more closely with the medical staff. In studying the medication, we concentrated on antiplatelet therapy and studied the use of aspirin alone compared to aspirin plus clopidogrel. Of the 659 patients only 172 received aspirin as a preventive agent. We noticed that during this study only a low number of patients received ASA treatment and it could be seen in the outcome of the illness. We also found that dual antiplatelet therapy did not decrease the incidence of reinfarction in patients with AMI. Discussion: In this study the theory (guidelines, other studies) and the clinical practice of the therapy and medication of AMI were compared. ASA therapy did not produce any significant effect. Our results are similar to those studies which concluded that ASA did not decrease the risk of cardiovascular events. Conclusion: Most patients with AMI suffer from polymorbidity. Since the occurrence of underlying chronic diseases is high, not only AMI must be treated, but therapy and medication must be complex. Complex therapeutic management is the key to the success of pharmaceutical care in the community pharmacy following hospital treatment.",
keywords = "Acute myocardial infarction, Complex therapy, Patients Polymorbid, Pharmaceutical care",
author = "M{\'a}rton Argay and Istv{\'a}n Ko{\'o}s and Istv{\'a}n Tak{\'a}cs and Irina Dormaeva and Andrea Mesk{\'o} and R. Zelk{\'o} and Bal{\'a}zs Hank{\'o}",
year = "2013",
month = "2",
doi = "10.5414/CP201592",
language = "English",
volume = "51",
pages = "91--95",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Pharmaceutical care for patients with acute myocardial infarction in Hungary

AU - Argay, Márton

AU - Koós, István

AU - Takács, István

AU - Dormaeva, Irina

AU - Meskó, Andrea

AU - Zelkó, R.

AU - Hankó, Balázs

PY - 2013/2

Y1 - 2013/2

N2 - Objective: To obtain information on the main causatives of acute myocardial infarction (AMI), the background needs to be analyzed. Our aim was to identify those pharmaceutical aspects of this polymorbidity where the pharmacist can contribute. Earlier and recent European and Hungarian studies show similar results: cardiovascular (CV) death is still the leading cause of mortality. The quality of life is much lower and life expectancy is shorter in the investigated Borsod-Abaúj Zemplén county population compared to the whole of the country. After pharmaceutical care has been defined, its role should be established. Methods: A retrospective hospital-based survey was carried out. Medical records of 659 patients treated for myocardial infarction at the 1 st Department of Internal Medicine-Cardiology of Borsod-Abaúj- Zemplén County Hospital and University Hospital were analyzed. Data were obtained using the MedWorkS integrated hospital information system and were selected based on Social Security Number (TAJ) and The International Statistical Classification of Diseases and Related Health Problems (ICD). We focused on the therapy and medication of patients. Results: The obtained results are consistent with those of previous Hungarian studies (OLEF 2000) and statistical analyses. Based on the present study we suggest that pharmacists should work more closely with the medical staff. In studying the medication, we concentrated on antiplatelet therapy and studied the use of aspirin alone compared to aspirin plus clopidogrel. Of the 659 patients only 172 received aspirin as a preventive agent. We noticed that during this study only a low number of patients received ASA treatment and it could be seen in the outcome of the illness. We also found that dual antiplatelet therapy did not decrease the incidence of reinfarction in patients with AMI. Discussion: In this study the theory (guidelines, other studies) and the clinical practice of the therapy and medication of AMI were compared. ASA therapy did not produce any significant effect. Our results are similar to those studies which concluded that ASA did not decrease the risk of cardiovascular events. Conclusion: Most patients with AMI suffer from polymorbidity. Since the occurrence of underlying chronic diseases is high, not only AMI must be treated, but therapy and medication must be complex. Complex therapeutic management is the key to the success of pharmaceutical care in the community pharmacy following hospital treatment.

AB - Objective: To obtain information on the main causatives of acute myocardial infarction (AMI), the background needs to be analyzed. Our aim was to identify those pharmaceutical aspects of this polymorbidity where the pharmacist can contribute. Earlier and recent European and Hungarian studies show similar results: cardiovascular (CV) death is still the leading cause of mortality. The quality of life is much lower and life expectancy is shorter in the investigated Borsod-Abaúj Zemplén county population compared to the whole of the country. After pharmaceutical care has been defined, its role should be established. Methods: A retrospective hospital-based survey was carried out. Medical records of 659 patients treated for myocardial infarction at the 1 st Department of Internal Medicine-Cardiology of Borsod-Abaúj- Zemplén County Hospital and University Hospital were analyzed. Data were obtained using the MedWorkS integrated hospital information system and were selected based on Social Security Number (TAJ) and The International Statistical Classification of Diseases and Related Health Problems (ICD). We focused on the therapy and medication of patients. Results: The obtained results are consistent with those of previous Hungarian studies (OLEF 2000) and statistical analyses. Based on the present study we suggest that pharmacists should work more closely with the medical staff. In studying the medication, we concentrated on antiplatelet therapy and studied the use of aspirin alone compared to aspirin plus clopidogrel. Of the 659 patients only 172 received aspirin as a preventive agent. We noticed that during this study only a low number of patients received ASA treatment and it could be seen in the outcome of the illness. We also found that dual antiplatelet therapy did not decrease the incidence of reinfarction in patients with AMI. Discussion: In this study the theory (guidelines, other studies) and the clinical practice of the therapy and medication of AMI were compared. ASA therapy did not produce any significant effect. Our results are similar to those studies which concluded that ASA did not decrease the risk of cardiovascular events. Conclusion: Most patients with AMI suffer from polymorbidity. Since the occurrence of underlying chronic diseases is high, not only AMI must be treated, but therapy and medication must be complex. Complex therapeutic management is the key to the success of pharmaceutical care in the community pharmacy following hospital treatment.

KW - Acute myocardial infarction

KW - Complex therapy

KW - Patients Polymorbid

KW - Pharmaceutical care

UR - http://www.scopus.com/inward/record.url?scp=84873842398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873842398&partnerID=8YFLogxK

U2 - 10.5414/CP201592

DO - 10.5414/CP201592

M3 - Article

VL - 51

SP - 91

EP - 95

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 2

ER -